The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that the first patient has been dosed in ...

Reports Q1 revenue EUR 75M vs. EUR 62.4M last year. “We are making progress toward the planned separation announced early this year, ...

Q1 2025 Management View CEO Paul Stoffels highlighted the appointment of Henry Gosebruch as the CEO of SpinCo, marking ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma. The EMA’s ...

After almost two decades of serving Blue Springs as a police officer, the city is now giving back to Lt. Brandon Claxton as ...

C4 Therapeutics, Inc.’s CCCC share price has surged by 17.60%, which has investors questioning if this is right time to sell.

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

Revlimid was previously only licensed as a third-line treatment for mantle cell lymphoma (MCL), another form of indolent (slow-growing) NHL, as well as multiple myeloma, and the new indication ...